In January 2019, ICER launched a year-long project to engage with experts, US stakeholders, and influential international agencies to develop, test, and build consensus around methodological options for determining value-based prices for potential cures. ICER will ultimately create a roadmap for value assessment of potential cures that will have a direct and significant impact on coverage and pricing recommendations for the coming generation of innovative new treatments.
For questions, please contact firstname.lastname@example.org.
On September 17, ICER hosted a full-day meeting of invited stakeholders to gather additional input on whether and how to adapt its standard assessment methods for SSTs. The meeting was livestreamed, and the recordings of each session can be found here:
Below you will find the final documents from the policy paper review process: